Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2021 16:05 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

SAN FRANCISCO and SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
November 01, 2021 08:00 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study

BRAF clinical-genomic landscape research initiative to investigate real-world data from more than 175,000 patients across tumor types, patient demographics and treatment settings Preliminary analyses...
October 28, 2021 16:05 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer

SAN FRANCISCO and SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
October 07, 2021 09:00 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference

SAN FRANCISCO and SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
September 30, 2021 16:30 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference

SAN FRANCISCO and SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
September 13, 2021 08:00 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference

SAN FRANCISCO and SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
August 16, 2021 16:05 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results

Announced first patient dosed in Phase 1 trial evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors Strengthened management team and Board of Directors with key appointments ...
July 27, 2021 08:00 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. to Participate in the 2021 Wedbush PacGrow Healthcare Conference

SAN FRANCISCO and SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
July 07, 2021 16:05 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021

SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
June 28, 2021 08:00 ET | Source: Kinnate Biopharma

Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors

SAN FRANCISCO and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right